All Chimeric Antigen Receptors (CARs) articles – Page 3
-
ArticleDeveloping state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
-
ArticleAllogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
-
NewsScientists identify a biomarker that predicts CAR T-cell therapy efficacy
Combining AI with cutting-edge flow cytometry and massive sequencing technologies, researchers describe CAR T cell characteristics that determine their therapeutic capacity for the first time.
-
NewsLife-saving approach may overcome persistent obstacles to cell transplantation and immunotherapy
In their study, researchers duped antibodies with a decoy to prevent rejection of transplanted cells.
- Previous Page
- Page1
- Page2
- Page3
- Next Page